Following encouraging trial results, retatrutide, a innovative peptide treatment for managing type 2 metabolic disorder, has secured regulatory approval from the Healthcare and Regulatory Agency ( MHRA body). Limited availability is currently anticipated via dedicated obesity centres and certain NHS organisations in coming 2024 , with more exten… Read More